Novartis AG
USE OF A H3R INVERSE AGONIST FOR THE TREATMENT OF SHIFT WORK DISORDER
Last updated:
Abstract:
The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder.
Status:
Application
Type:
Utility
Filling date:
20 Dec 2021
Issue date:
16 Jun 2022